| label
|
?typeLabel
|
?trialLabels
|
developer
|
funder
|
manufacturer
|
| Gam-COVID-Vac
|
adenovirus-based vaccine
|
phase I clinical trial, phase II clinical trial, phase III clinical trial
|
Gamaleya Research Institute of Epidemiology and Microbiology
|
|
|
| University of Queensland COVID-19 vaccine candidate
|
protein subunit vaccine
|
phase I clinical trial
|
University of Queensland
CSL Limited
|
Coalition for Epidemic Preparedness Innovations
|
Sypharma
CSL Limited
Seqirus (global)
|
| Lunar-COV19
|
Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects
|
phase I clinical trial, phase II clinical trial
|
Duke–NUS Medical School
Arcturus Therapeutics
|
|
Catalent Pharma Solutions
|
| SCB-2019
|
protein subunit vaccine
|
phase I clinical trial
|
GSK
Dynavax Technologies (United States)
|
Coalition for Epidemic Preparedness Innovations
|
Clover Biopharmaceuticals Inc.
|
| mRNA-1273 vaccine
|
Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection
|
phase I clinical trial, phase II clinical trial, phase III clinical trial
|
Moderna
National Institute of Allergy and Infectious Diseases
Medidata Solutions
|
Biomedical Advanced Research and Development Authority
Coalition for Epidemic Preparedness Innovations
Operation Warp Speed
|
Moderna
Catalent Pharma Solutions
Lonza Group
Rovi
Bioqual
Takeda Pharmaceutical Company
|
| AG0301-COVID19
|
DNA vaccine
|
phase I clinical trial, phase II clinical trial
|
Osaka University
Takara Bio
|
|
AnGes
Takara Bio
Cytiva
Brickell Biotech, Inc.
|
| GX-19
|
DNA vaccine
|
phase I clinical trial, phase II clinical trial
|
Genexine (South Korea)
GenNBio Inc
International Vaccine Institute
KAIST
Pohang University of Science and Technology
|
|
BINEX Co. Ltd.
PT Kalbe Farma Tbk
|
| CoronaVac
|
inactivated vaccine
|
phase I clinical trial, phase II clinical trial, phase III clinical trial
|
Sinovac Biotech
Instituto Butantan
Bio Farma
|
Sinovac Biotech
|
Sinovac Biotech
|
| bacTRL-Spike
|
DNA vaccine
|
phase I clinical trial
|
Symvivo
|
National Research Council Canada
|
|
| AZD1222
|
adenovirus-based vaccine
|
phase I clinical trial, phase II clinical trial, phase III clinical trial
|
Jenner Institute
Oxford BioMedica
University of Oxford
Vaccines Manufacturing and Innovation Centre
Pall Corporation
Cobra Biologics (United Kingdom)
AstraZeneca
|
Coalition for Epidemic Preparedness Innovations
Biomedical Advanced Research and Development Authority
Government of the United Kingdom
GAVI
Operation Warp Speed
|
Oswaldo Cruz Foundation
Serum Institute of India
HALIX B.V.
Advent SRL
Merck KGaA
Vaccitech
AstraZeneca
SK Bioscience
JCR Pharmaceuticals
|
| Ad5-nCoV
|
adenovirus-based vaccine
|
phase I clinical trial, phase II clinical trial, phase III clinical trial
|
CanSino Biologics
PLA Academy of Military Medical Sciences
|
|
Petrovax
|
| VXA-CoV2-1
|
adenovirus-based vaccine
|
phase I clinical trial
|
Vaxart
Emergent BioSolutions
|
|
|
| BBIBP-CorV
|
inactivated vaccine
|
phase I clinical trial, phase II clinical trial, phase III clinical trial
|
Beijing Institute of Biological Products Co., Ltd
|
|
|
| AdimrSC-2f
|
protein subunit vaccine
|
phase I clinical trial
|
Adimmune Corporation
|
|
|
| Medicago Inc. COVID-19 vaccine candidate
|
virus-like particle vaccine
|
phase I clinical trial
|
Laval University
Medicago
|
|
|
| LNP-nCoVsaRNA
|
Clinical trial to assess the safety of a coronavirus vaccine in healthy men and women
|
phase I clinical trial
|
Imperial College London
VacEquity Global Health
|
Morningside Venture Capital
|
|
| Sanofi/GSK SARS-CoV-2 subunit vaccine
|
protein subunit vaccine
|
phase I clinical trial, phase II clinical trial
|
Sanofi Pasteur
GSK
|
Biomedical Advanced Research and Development Authority
United States Department of Health and Human Services
United States Department of Defense
|
|
| COVAX-19
|
protein subunit vaccine
|
phase I clinical trial
|
Flinders University
Oracle
Vaxine
|
|
Medytox Korea Co., Ltd.
Sypharma
Oxford Expression Technologies Ltd.
|
| ZyCoV-D
|
DNA vaccine
|
phase I clinical trial, phase II clinical trial
|
Cadila Healthcare
|
|
|
| hAd5-S-Fusion+N-ETSD
|
adenovirus-based vaccine
|
phase I clinical trial
|
ImmunityBio
|
|
|
| NVX-CoV2373
|
protein subunit vaccine
|
phase I clinical trial, phase II clinical trial, phase III clinical trial
|
Novavax
Emergent BioSolutions
Serum Institute of India
AGC Biologics
|
Coalition for Epidemic Preparedness Innovations
United States Department of Defense
Bill & Melinda Gates Foundation
Operation Warp Speed
|
Fujifilm Diosynth Biotechnologies
SK Bioscience
Praha Vaccines
Biofabri
Takeda Pharmaceutical Company
PolyPeptide Group
Endo International plc
Biologics Manufacturing Centre
|
| EpiVacCorona
|
protein subunit vaccine
|
phase I clinical trial, phase II clinical trial
|
State Research Center of Virology and Biotechnology VECTOR
|
|
|
| UB-612
|
protein subunit vaccine
|
phase I clinical trial
|
Covaxx
University of Nebraska Medical Center
United Biomedical, Inc., Asia
|
Ministry of Health and Welfare
|
DASA S.A.
|
| Institute of Medical Biology COVID-19 vaccine candidate
|
inactivated vaccine
|
phase I clinical trial, phase II clinical trial
|
Institute of Medical Biology
Peking Union Medical College
Chinese Academy of Medical Sciences
|
Chinese Academy of Medical Sciences
|
|
| Ad26.COV2.S
|
adenovirus-based vaccine
|
phase I clinical trial, phase II clinical trial, phase III clinical trial
|
Janssen Pharmaceutica
Beth Israel Deaconess Medical Center
|
Biomedical Advanced Research and Development Authority
Operation Warp Speed
|
Emergent BioSolutions
Catalent Pharma Solutions
Biological E. Limited
Grand River Aseptic Manufacturing
|
| INO-4800
|
DNA vaccine
|
phase I clinical trial, phase II clinical trial
|
Inovio Pharmaceuticals
Advaccine Biotechnology Co. Ltd.
International Vaccine Institute
Seoul National University Hospital
|
Coalition for Epidemic Preparedness Innovations
Bill & Melinda Gates Foundation
United States Department of Defense
Operation Warp Speed
|
VGXI, Inc.
Richter-Helm BioLogics GmbH & Co. KG.
Ology Bioservices, Inc.
Thermo Fisher Scientific Inc.
|
| RBD SARS-CoV-2 HBsAg VLP
|
virus-like particle vaccine
|
phase I clinical trial, phase II clinical trial
|
SpyBiotech
Serum Institute of India
|
|
|
| zorecimeran
|
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults
|
phase I clinical trial, phase II clinical trial
|
CureVac
|
Coalition for Epidemic Preparedness Innovations
Government of the Federal Republic of Germany
European Investment Bank
Bill & Melinda Gates Foundation
Defense Advanced Research Projects Agency
|
|
| MVC COVID-19 Vaccine
|
protein subunit vaccine
|
phase I clinical trial
|
Medigen Vaccine Biologics
National Institute of Allergy and Infectious Diseases
|
|
Dynavax Technologies (United States)
Medigen Vaccine Biologics
|
| V591
|
replicating viral vector vaccine
|
phase I clinical trial, phase II clinical trial
|
Pasteur Institute
University of Pittsburgh Center for Vaccine Research
|
|
Merck & Co.
|
| Anhui Zhifei Longcom Biopharmaceutical COVID-19 vaccine candidate
|
protein subunit vaccine
|
phase I clinical trial, phase II clinical trial
|
Anhui Zhifei Longcom Biopharmaceutical
Institute of Microbiology
|
|
Anhui Zhifei Longcom Biopharmaceutical
|
| QazCovid-in
|
inactivated vaccine
|
phase I clinical trial, phase II clinical trial
|
Research Institute for Biological Safety Problems
|
|
|
| Arcov
|
A Phase I clinical trial to evaluate the safety, tolerance and preliminary immunogenicity of different doses of a SARS-CoV-2 mRNA vaccine in population aged 18-59 years and 60 years and above
|
phase I clinical trial
|
Peking Union Medical College
|
|
Walvax Biotechnology Co., Ltd.
|
| Covaxin / BBV152
|
inactivated vaccine
|
phase I clinical trial, phase II clinical trial
|
Bharat Biotech International
Indian Council of Medical Research
National Institute of Virology
|
|
Bharat Biotech International
|
| Finlay-FR-1
|
protein subunit vaccine
|
phase I clinical trial, phase II clinical trial
|
Finlay Vaccine Institute
|
|
|
| GRAd-COV2
|
adenovirus-based vaccine
|
phase I clinical trial
|
ReiThera Srl
Leukocare AG
Lazzaro Spallanzani National Institute for Infectious Diseases
|
|
Univercells (Belgium)
|
| Pfizer–BioNTech COVID-19 vaccine
|
Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults
|
phase I clinical trial, phase II clinical trial, phase III clinical trial
|
BioNTech
Pfizer
|
Operation Warp Speed
Government of the Federal Republic of Germany
|
Pfizer
Rentschler Biopharma SE
Behringwerke
BioNTech
Baxter International
|